Goldman Sachs
TBPH icon

Goldman Sachs’s Theravance Biopharma TBPH Stock Holding History

Goldman Sachs’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$561K – 6222
2022
Q4 		$561K Hold
50,000
– – ﹤0.01% 4809
2022
Q3 		$507K Buy
+50,000
New +$469K ﹤0.01% 4961

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs's TBPH Position: Q2 2026 in Review

Goldman Sachs reduced its Theravance Biopharma (TBPH) stake by 18% in Q2 2026, selling an estimated $1.26M and leaving 339,960 shares worth $5.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

Goldman Sachs first reported a position in TBPH in Q2 2014 and has held it in 45 quarters since. The position peaked at $11.4M in Q1 2018. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Goldman Sachs held 339,960 shares of Theravance Biopharma worth $5.78M as of Q2 2026.
  • Goldman Sachs sold 76,183 Theravance Biopharma shares in Q2 2026, an estimated $1.26M.
  • Theravance Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3762 holding.
  • Goldman Sachs first reported a position in Theravance Biopharma in Q2 2014 and has held it in 45 quarters since.
  • Goldman Sachs's Theravance Biopharma position peaked at $11.4M in Q1 2018.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.